Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 73.9%

Neg 0% Neu 0% Pos 73.9%

Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $50 to $60.